CD137

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

Retrieved on: 
Wednesday, December 6, 2023
Patient, Dynamics (music), CD137, University, Toxicity, Safety, Therapy, Pharmaceutical industry

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

Key Points: 
  • Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
    Crescendo expands trial of lead programme first-in-class, bispecific Humabody®, CB307 beyond Europe with first US trial site, the Fred Hutchinson Cancer Centre, at the University of Washington
    Cambridge, UK, 6 December 2023 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that the first patients in the U.S. have been dosed as part of the ongoing Phase 1b study of CB307, Crescendo’s lead programme in PSMA+ metastatic castration-resistant prostate cancer (mCRPC).
  • CB307 is a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity.
  • The ongoing dose expansion part of the Phase 1b POTENTIA trial ( NCT04839991 ) comprises two cohorts, assessing the safety and efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
  • The US part of the trial has seen patients successfully dosed in both the monotherapy and combination cohorts at the Fred Hutchinson Cancer Centre.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Patient, Pancreatic cancer, Ki-67 (protein), AACR, Amphetamine, Biomarker, AMP, Vaccine, Antigen, CD4, Lymph, CD137, Conference, KRAS, Phenotype, Development, CD8, Mouse, SITC, Tissue, Immunotherapy, Granzyme, Neoplasm, Risk, Research and development, Annual general meeting, Flow cytometry, RFS, V600E, Cancer, Therapy, CpG, Death, Peptide, BRAF, Pharmaceutical industry, Amphiphile, Research, Doctor of Philosophy

The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.

Key Points: 
  • The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.
  • The data will be presented at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) taking place at the San Diego Convention Center in San Diego, CA and virtually from November 1-5, 2023.
  • ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909).
  • 90% of immune responders had T cell responses to ≥ two mKRAS antigens, with 35% responding to all seven mKRAS antigens evaluated.

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

Retrieved on: 
Thursday, November 2, 2023
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, ATM, Food, Progression-free survival, Public offering, Therapy, Thromboxane A2, Transitional epithelium, Bicycle, Pembrolizumab, CD137, CMC, PFS, Research and development, Participation, Exercise, R, RSVP, Novartis, Webcast, ORR, BTC, Food and Drug Administration, Pharmaceutical industry, Vaccine, Life insurance, Cryptocurrency, Bayer, Chemistry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.
  • “In the third quarter, we took important steps toward achieving our goal of quickly getting our novel therapies to those who need them.
  • In September, Bicycle Therapeutics announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the FDA.
  • In addition, the company also received net proceeds from Bicycle’s at-the-market (ATM) offering program during the third quarter of 2023 totaling $19.4 million.

Agenus Reports Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Inc., Non-small-cell lung cancer, SGO, Sarcoma, CRC, Gastrointestinal cancer, Metastasis, Annual general meeting, ESMO, Survival, Fast Track, NSCLC, Immunotherapy, Melanoma, ASCO, PROC, Biologics license application, Clinical trial, Standard of care, Patient, Colorectal cancer, Cancer, Growth, Financial toxicity, MOS, FDA, CD137, ORR, Pharmaceutical industry, Mineral wool, Vaccine

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023.

Key Points: 
  • Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023.
  • Sarcomas: Updated data for a Phase 1b cohort with advanced sarcomas to be presented at ESMO on October 21st 2023.
  • Second Quarter 2023 Financial Results:
    We ended our second quarter 2023 with a cash, cash equivalent and short-term investment balance of $157.6 million, compared to $193.4 million at December 31, 2022.
  • Our net loss includes non-cash expenses of $28.9 million for the three months ended, and $53.8 million for the six months ended, June 30, 2023.

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

Retrieved on: 
Monday, July 24, 2023
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Acceleration, AACR, Therapy, VH, Takeda, Sofinnova, IP Group, Trial of the century, Dynamics (music), PD-1, CD137, Vaccine

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.

Key Points: 
  • Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort.
  • CB307, Crescendo’s lead proprietary programme, is now entering the cohort expansion part of the ongoing Phase 1b clinical trial.
  • The monotherapy expansion cohort is already underway in individuals with PSMA+ metastatic castration-resistant prostate cancer (mCRPC) in a last-line setting.
  • “We are delighted to have secured this additional financing which will enable us to accelerate the clinical development of CB307,” commented Theodora Harold, CEO at Crescendo Biologics.

Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO

Retrieved on: 
Monday, June 5, 2023
Oncology, Health, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Hepatotoxicity, Neoplasm, American Society of Clinical Oncology, Infection, Cancer, Immunotherapy, ASCO, MD, Patient, Annual general meeting, Liver, Society, CD137, Medical imaging, Pharmaceutical industry, Palladium, Vaccine, Agenus

AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors.

Key Points: 
  • AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors.
  • “AGEN2373 has shown meaningful single agent activity and a favorable safety profile without evidence of liver toxicity in patients with heavily pretreated cold and immunotherapy resistant tumors,” said Dr. Steven O’Day, MD, Chief Medical Officer at Agenus.
  • “AGEN2373 is designed to selectively boost tumor immunity while limiting hepatotoxicity and off-target effects associated with systemic CD137 activation.
  • Presently, AGEN2373 is being evaluated in combination with botensilimab (multi-functional anti-CTLA-4) at a dose of 10 mg/kg in patients with PD-(L)1 refractory melanoma.

Global CD137 Antibodies Clinical Trials Research Report 2023: Insights on More Than 60 CD137 Antibodies in Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Lymphoma, Monoclonal antibody, TNF, Prevalence, Anticalin, CD3, HER2, Roche, Indication, Cancer, NK, CD137, Bristol Myers Squibb, GNC, Antibody, Lung cancer, Monoclonality, Hematological Cancer Research Investment and Education Act, CD137L, Protein, Patient, Drug combination, Compass, Urelumab, Observation, Merck, Leukemia, Therapy, Pembrolizumab, Stomach, PD-L1, Family, Vaccine, Pharmaceutical industry, Pfizer

The "Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD137 Antibodies Clinical Trials & Market Trends Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • The therapeutic potential of CD137 has been investigated exhaustively and has now been confirmed as studies from running clinical and research studies emerge.
  • Utomilumab and Urelumab were among the first CD137 agonists to be developed and introduced in human clinical trials.
  • Global CD137 Antibodies Clinical Trials Insight by Company, Indication & Phase
    CD137 Therapeutic Approaches by Monoclonal, Bispecific, Trispecific & Tetraspecific Antibodies

Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Biotechnology, Health, Oncology, Clinical Trials, Abstract, University, Sarcoma, NCT, American Society of Clinical Oncology, Hepatotoxicity, Cancer, Infection, Publication, ASCO, MD, Patient, Doxorubicin, Clinical research, Annual general meeting, CDT, PD-1, Society, Conference, CD137, Pharmaceutical industry

Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL.

Key Points: 
  • Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL.
  • Data from a single-arm, open-label Phase 2 study of balstilimab (PD-1 antagonist) and zalifrelimab (first generation CTLA-4 antagonist) plus doxorubicin in patients with advanced sarcomas will be presented at an oral session on Monday, June 5 from 11:30am - 2:30pm CDT.
  • Complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) in patients with advanced solid tumors will be presented at a poster discussion on Saturday, June 3rd from 3:00pm - 4:30pm CDT.
  • Data presented at the conference will be available to view in the Publications section of the Agenus website ( https://agenusbio.com/publications ) following the ASCO Conference.

Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Retrieved on: 
Friday, April 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, AACR, Therapy, Pharmacokinetics, Publication, Malignancy, Patient, Neoplasm, CD137, Safety, Vaccine

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.
  • Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA™
    Title: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle® tumor-targeted immune cell agonist®
    Title: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with Nectin-4 associated advanced malignancies
    The posters will be made available on the Publications section of bicycletherapeutics.com following the presentations.